Job Placement · Biotech and Life Sciences · QA / Regulatory Manager
Biotech QA and regulatory manager placement on milestone billing, not contingency. Managers own the release decision, the submission signature and the quality system, priced by BLS's all-other-managers code at a 141,900 median, though inspection-hosting candidates in the right FDA pathway sit at 186,300 to 238,270. BEG fills the seat in 23 to 35 days from 12,864.
See your exact placement price - no call required
See pricing before you talk to anyone. No demo gate, no obligation, and no co-employment.
TL;DR
When an FDA inspector opens a CGMP audit or pulls the audit trail behind an electronic record under 21 CFR Part 11, the QA/regulatory manager is the name who answers for it, since a drug made outside CGMP is legally adulterated whether or not anything is actually wrong with it, and Part 11's validation and retention provisions are enforced at the manager's own discretion call, not a fixed checklist. That exposure is what separates this seat from the 141,900 median BLS publishes for the manager code it sits under: someone who has actually stood behind an inspection and a validated system already earns 186,300 to 238,270, a fact BEG prices the search around rather than against a resume that has never been tested by an inspector.
Why This Search Stalls
The credential that matters here is not a filing history but an inspection survived: has this person actually stood in the room when FDA opened a CGMP audit and answered for the quality system afterward. That experience concentrates in the 186,300 to 238,270 band, well above the 141,900 median the seat gets posted at, so firms benchmarking to the median mostly interview people who have prepared for an inspection rather than lived through one.
How BEG Fills This Seat
BEG scopes the seat to actual signature authority, sources for the exact FDA center and pathway the lead program needs, and prices the equity question before the offer goes out, not after it is declined.
| Step | What it requires | Where it stalls |
|---|---|---|
| Scope the signature authority | A job description for the release decision or submission signature, the quality system, and the specialists who report in | Write the job description around drafting and review tasks, and it reads like the specialist role one level down, so candidates who actually hold signature authority skip right past it |
| Source for the exact FDA pathway | A manager who has filed with the specific FDA center, CDER or CBER, and pathway the lead program will use, and hosted an inspection | Someone who has both filed in the right pathway and personally hosted an inspection does not apply to a posting priced at 141,900; that combination sits at 186,300 to 238,270 and stays there |
| Price the equity question | Clarity on whether the offer includes equity tied to a program that has not yet read out | Silence on equity reads as an absence of it, so a finalist already vesting somewhere else treats a median cash number as the whole offer and passes without asking what else might be on the table |
| Close against modality mismatch | A wage and equity package that reflects the gap between the 141,900 median and the 238,270 90th percentile | A board that finally sets the equity number two weeks after the finalist accepted somewhere else has confirmed the modality mismatch was never really the obstacle, the timing was |
FDA’s enforcement-discretion guidance on Part 11 does not name which legacy systems are exempt, it leaves that judgment call to the manager on record, so a reference conversation about a specific validation decision this candidate actually made tells BEG more than a list of software platforms on a resume.
Milestone Billing Against Contingency
BEG’s Tier III fee holds at $12,864 to $15,437 whether the winning candidate’s validation and inspection history commands median pay or the 90th percentile. A contingency invoice climbs right along with that number instead, since it is calculated off the final salary, not off what the seat is actually worth to source.
The QA/Regulatory Manager Math
FDA’s own remedies for a CGMP or Part 11 failure, product seizure, an injunction, a held release, are what price this seat above a generalist compliance officer, and BEG’s fee tracks that premium without inflating to match it. $12,864 to $15,437 covers 45 to 54 percent of a 20 percent cut of the $141,900 manager median, 59 to 71 percent of one at the $109,010 compliance officer 75th percentile, and 48 to 58 percent at the $133,720 90th (BLS). Contingency pricing gets more expensive exactly where the inspection history gets more valuable; BEG’s does not.
Contingency, BEG, or Temp
The audit and release-signature exposure this seat carries is exactly what a percentage-of-salary fee prices worst, since that fee climbs with the base while the actual risk BEG is sourcing against, an untested quality system, never shows up in a salary number at all.
| Model | Who employs | How you pay | Right when |
|---|---|---|---|
| Contingency recruiter | Your company, direct, exactly as with BEG | 20 to 25 percent of whatever the final salary turns out to be, invoiced the day the hire starts | The role is compensation-only sensitive and nobody minds the fee rising if the winning candidate commands top-of-band pay |
| BEG milestone placement | Your company, direct hire, on the same terms as the row above | $12,864 to $15,437, fixed regardless of the final offer, released as the search hits its stages | The inspection and validation history matters more than shaving a few points off a percentage fee |
| Staffing or temp agency | The staffing firm, which keeps this manager on its own payroll throughout | An hourly rate plus markup, running for as long as the assignment is needed | A site needs someone signing off on releases for the next few months, not a permanent quality lead |
The release signature and the CGMP or Part 11 exposure behind it are what this fee is actually pricing, not a specialist’s documentation work one tier down. The full ladder of biotech seats BEG places sits on the hub.
FAQ
The manager owns the quality management system or the regulatory strategy for a product, the release decision or the submission signature, the inspection response, and the specialists who prepare that work. A specialist drafts the underlying documents; a director oversees several products at once.
Firms want a manager who has filed with their exact FDA center and pathway and has hosted an inspection, but that experience is priced at the 186,300 to 238,270 upper range or held by someone with unvested equity in an unread program. A cash offer at the 141,900 median without addressing equity is often declined.
BLS prices the manager code regulatory and QA managers fall under at a 141,900 median, with the middle half running 102,880 to 186,300, the top decile above 238,270, and the bottom decile at 74,300 for the most junior managers in the code.
BEG’s fee for this seat is fixed at Tier III, 12,864 to 15,437, billed in stages against the search rather than as a percentage of a large base salary, and it does not change with how the equity portion of the manager’s offer is negotiated.
This manager search runs on the standard 23 to 35 day timeline BEG holds across the vertical, with an 86 percent fill rate, though the pool takes longer to qualify than the broader managers, all other code suggests: BLS projects that code to add 65,600 jobs on a 1,338,800 base, 5 percent growth, but biotech QA and regulatory manager searches draw from candidates well past its bachelor’s-plus-five-years typical entry point.
The RAPS Regulatory Affairs Certification, RAC-Drugs or RAC-Devices, requiring three years of experience with a bachelor’s degree, two with a master’s, or one with a doctorate. The credential lapses if the holder does not recertify.
FDA can pursue seizure or injunction for CGMP violations even without evidence of a product defect, and 21 CFR Part 11 has governed electronic records since August 20, 1997, with the manager deciding which legacy systems still need validation.
A specialist owns an assigned record or submission section and the audit trail behind it. A manager owns the release decision or the submission signature and the specialists who prepare that work, which is why BEG prices the manager seat at Tier III against the specialist’s Tier II.
The QA / regulatory specialist role one tier down drafts the records this manager signs off on; the director of clinical / regulatory seat above owns that same signature authority across several products at once, not one. Every biotech role BEG places is on the Biotech and Life Sciences hub.
More Biotech and Life Sciences placement
Ready?
Answer a few questions, get your exact number in about 90 seconds. No call required, no commitment.
See your exact placement price - no call required
